Morange P E, Lijnen H R, Alessi M C, Kopp F, Collen D, Juhan-Vague I
Haematology Laboratory, CHU Timone, Marseilles, France.
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1150-4. doi: 10.1161/01.atv.20.4.1150.
An increased plasma plasminogen activator inhibitor-1 (PAI-1) level is a risk factor for myocardial infarction, particularly when associated with visceral obesity. Although the link between PAI-1 and obesity is well documented, little is known about the physiological relevance of PAI-1 production by adipose tissue. Therefore, we have compared adipose tissue development and insulin resistance plasma parameters in PAI-1-deficient mice (PAI-1(-/-)) and wild-type littermates (PAI-1(+/+)) in a model of nutritionally induced obesity. After 17 weeks of consuming a high-fat diet (HFD), PAI-1(+/+) mice showed marked obesity, with a 52% increase in body weight compared with mice that were kept on a standard fat diet (P<0.0001). This weight gain was accompanied by adipocyte hypertrophy and an increase in the number of stroma cells in the gonadal fat pad, expressed as stroma cells/adipocytes (0.67+/-0.05 versus 0.43+/-0. 02; P<0.001). In plasma, the HFD induced a marked increase in PAI-1 antigen (5.1+/-0.56 versus 2+/-0.22 ng/mL; P<0.001), fasting insulinemia (1.1+/-0.21 versus 0.21+/-0.04 ng/mL; P<0.001), and glycemia (7.4+/-0.5 versus 5+/-0.3 mmol/L; P<0.001), whereas plasma triglyceride levels were not affected. When we compared PAI-1(-/-) and PAI-1(+/+) mice on the HFD, PAI-1(-/-) mice gained weight faster than did PAI-1(+/+) mice, with a significant difference in body weight between 3 and 8 weeks of the diet (32+/-1.7 versus 26+/-1.6 g at 6 weeks; P<0.05). After 17 weeks of the HFD, its effect on weight gain and the number and size of adipocytes was similar in PAI-1(+/+) and PAI-1(-/-) mice. By contrast, the increase in the number of stroma cells presented by PAI-1(+/+) mice was not observed in PAI-1(-/-) mice. In obese PAI-1(-/-) mice, tissue-type PA activity and antigen levels in the gonadal fat pad were significantly higher than in obese PAI-1(+/+) mice (230+/-50 versus 47+/-20 arbitrary units/g, P<0.01; 40+/-13 versus 17+/-13 ng/g, P<0.05, respectively), whereas urokinase-type PA activity and antigen levels were similar in both groups. In plasma, nonobese PAI-1(-/-) mice displayed 62% higher insulin levels (P<0.05) than did PAI-1(+/+) mice. Obese PAI-1(-/-) mice displayed 68% higher triglyceride levels (P<0.01) and 21% lower glucose levels (P<0.05) than did PAI-1(+/+) mice. These data support an effect of PAI-1 on weight gain and adipose tissue cellularity in the induction of obesity in mice. Moreover, PAI-1 influences glucidolipidic metabolism. The elevated expression of PAI-1 observed in human obesity could be involved in mechanisms that control adipose tissue development.
血浆纤溶酶原激活物抑制剂-1(PAI-1)水平升高是心肌梗死的一个危险因素,尤其是与内脏肥胖相关时。尽管PAI-1与肥胖之间的联系已有充分记载,但关于脂肪组织产生PAI-1的生理相关性却知之甚少。因此,我们在营养诱导肥胖模型中比较了PAI-1缺陷小鼠(PAI-1(-/-))和野生型同窝小鼠(PAI-1(+/+))的脂肪组织发育及胰岛素抵抗血浆参数。在食用高脂饮食(HFD)17周后,PAI-1(+/+)小鼠出现明显肥胖,与食用标准脂肪饮食的小鼠相比,体重增加了52%(P<0.0001)。体重增加伴随着脂肪细胞肥大以及性腺脂肪垫中基质细胞数量增加,以基质细胞/脂肪细胞表示(0.67±0.05对0.43±0.02;P<0.001)。在血浆中,HFD导致PAI-1抗原显著增加(5.1±0.56对2±0.22 ng/mL;P<0.001)、空腹胰岛素血症(1.1±0.21对0.21±0.04 ng/mL;P<0.001)和血糖(7.4±0.5对5±0.3 mmol/L;P<0.001),而血浆甘油三酯水平未受影响。当我们比较HFD喂养的PAI-1(-/-)和PAI-1(+/+)小鼠时,PAI-1(-/-)小鼠体重增加比PAI-1(+/+)小鼠更快,在饮食3至8周时体重有显著差异(6周时为32±1.7对26±1.6 g;P<0.05)。HFD喂养17周后,其对体重增加以及脂肪细胞数量和大小的影响在PAI-1(+/+)和PAI-1(-/-)小鼠中相似。相比之下,PAI-1(-/-)小鼠未观察到PAI-1(+/+)小鼠出现的基质细胞数量增加。在肥胖的PAI-1(-/-)小鼠中,性腺脂肪垫中的组织型纤溶酶原激活物(PA)活性和抗原水平显著高于肥胖的PAI-1(+/+)小鼠(分别为230±50对47±20任意单位/g,P<0.01;40±13对17±13 ng/g,P<0.05),而两组中的尿激酶型PA活性和抗原水平相似。在血浆中,非肥胖的PAI-1(-/-)小鼠的胰岛素水平比PAI-1(+/+)小鼠高62%(P<0.05)。肥胖的PAI-1(-/-)小鼠的甘油三酯水平比PAI-1(+/+)小鼠高68%(P<0.01),血糖水平低21%(P<0.05)。这些数据支持PAI-1对小鼠肥胖诱导过程中的体重增加和脂肪组织细胞构成有影响。此外,PAI-1影响糖脂代谢。在人类肥胖中观察到的PAI-1表达升高可能参与了控制脂肪组织发育的机制。